CL2007001630A1 - COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C. - Google Patents

COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C.

Info

Publication number
CL2007001630A1
CL2007001630A1 CL200701630A CL2007001630A CL2007001630A1 CL 2007001630 A1 CL2007001630 A1 CL 2007001630A1 CL 200701630 A CL200701630 A CL 200701630A CL 2007001630 A CL2007001630 A CL 2007001630A CL 2007001630 A1 CL2007001630 A1 CL 2007001630A1
Authority
CL
Chile
Prior art keywords
pirrolidinamide
hepatitis
treatment
pharmaceutical composition
compounds derived
Prior art date
Application number
CL200701630A
Other languages
Spanish (es)
Inventor
Sun Yat Sun Or Zhe Wang Ying
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001630(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of CL2007001630A1 publication Critical patent/CL2007001630A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200701630A 2006-06-06 2007-06-06 COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C. CL2007001630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81146406P 2006-06-06 2006-06-06
US50338506A 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
CL2007001630A1 true CL2007001630A1 (en) 2008-02-08

Family

ID=38832101

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200701630A CL2007001630A1 (en) 2006-06-06 2007-06-06 COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C.

Country Status (5)

Country Link
AR (1) AR063942A1 (en)
CL (1) CL2007001630A1 (en)
TW (1) TW200815481A (en)
UY (1) UY30391A1 (en)
WO (1) WO2007146695A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
US8268777B2 (en) 2007-12-05 2012-09-18 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
US8361958B2 (en) 2007-12-05 2013-01-29 Enanta Pharmaceuticals, Inc. Oximyl HCV serine protease inhibitors
EP2224920A4 (en) 2007-12-06 2012-05-09 Enanta Pharm Inc Process for making macrocyclic oximyl hepatitis c protease inhibitors
JP2011506472A (en) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド Macrocyclic oxymil hepatitis C serine protease inhibitor
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
CN102015652A (en) 2008-03-20 2011-04-13 益安药业 Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
CN104640572B (en) 2012-05-15 2018-04-27 索伦托医疗有限公司 Drug conjugates, coupling method, and application thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
EP4257191A3 (en) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
CN110904121B (en) * 2019-12-17 2022-11-29 南京农业大学 Application of susceptibility gene SR30 in improving crop resistance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
AR063942A1 (en) 2009-03-04
WO2007146695A1 (en) 2007-12-21
UY30391A1 (en) 2008-01-31
TW200815481A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
CL2007001630A1 (en) COMPOUNDS DERIVED FROM PIRROLIDINAMIDE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF HEPATITIS C.
CL2007002920A1 (en) COMPOUNDS DERIVED FROM 2-AMINOCARBONYLPIRIDINE; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
CL2007003226A1 (en) COMPOUNDS DERIVED FROM PIRIDINONA; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT CANCER.
CL2007002234A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF PROLIFERATIVE DISEASES.
CL2007003299A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE HEPATITIS C VIRUS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
CL2007002974A1 (en) COMPOUNDS DERIVED FROM BENZOIMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH DGAT1.
CL2007002327A1 (en) COMPOUNDS DERIVED FROM REPLACED FENIL-IMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF HCV.
CL2007003100A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINA, INHIBITORS OF CISTEINE PROTEASA; PREPARATION PROCESSES; SALES OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF MALARIA.
CL2007003244A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2007003138A1 (en) COMPOUNDS DERIVED FROM ANILINOPIPERAZINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
DK1868579T3 (en) Pharmaceutical composition comprising an omega-carboxyaryl sun-substituted diphenylurea for the treatment of cancer
CL2007003202A1 (en) COMPOUNDS DERIVED FROM ESPIROINDOLINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS.
CL2011000846A1 (en) Heterocyclic Substituted Compounds; pharmaceutical composition; and its use for the treatment of hepatitis c.
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2007002377A1 (en) COMPOUNDS DERIVED FROM QUINAZOLINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND ITS USE AS ANTICANCERIGENO.
CL2007002649A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES 2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL] -4-FLUORO- BENZONITRILE; AND USE FOR THE TREATMENT OF DIABETES.
BRPI0820665A2 (en) peptidyl nitrile compounds, processes for their manufacture, pharmaceutical composition, combination and use of said compounds
BRPI0806531A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND.
CL2007002733A1 (en) COMPOUNDS DERIVED FROM 2-ARIL-6-PHENYL-IMIDAZO [1,2-A] PIRIDINES; PROCEDURE FOR OBTAINING COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES, OSTEOPOROSIS AND CANCER.
BRPI0821115A2 (en) Aminotriazole-derived compound, drug, pharmaceutical composition and use of compound
CL2007003033A1 (en) COMPOUNDS DERIVED FROM BENZOILAMINO HETEROCICLOS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND USE OF THE COMPOUND IN THE TREATMENT OF TYPE II DIABETES.
CL2007002207A1 (en) COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA.